UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): May 24, 2021 (
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 19, 2021, Abeona Therapeutics Inc. (the “Company”) filed a Current Report on Form 8-K disclosing under Item 5.02 that Leila Alland, M.D. and Donald Wuchterl were appointed to serve on the Board of Directors (the “Board”) of the Company effective on April 14, 2021. At the time of this filing, Dr. Alland and Mr. Wuchterl had not been appointed to serve on any committees of the Board.
Pursuant to Instruction (2) to Item 5.02 of Form 8-K, the Company is filing this amendment to its prior Current Report on Form 8-K for the sole purpose of disclosing that (i) Dr. Alland will serve as a member of the Board’s Compensation Committee and its Nominating and Corporate Governance Committee and (ii) Mr. Wuchterl will serve as a member of the Board’s Nominating and Corporate Governance Committee. The committee appointments became effective as of May 24, 2021.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
May 28, 2021 | Abeona Therapeutics Inc. | |
(Registrant) | ||
By: | /s/ Brendan M. O’Malley | |
Name: | Brendan M. O’Malley | |
Title: | Corporate Secretary |
Cover |
Apr. 14, 2021 |
---|---|
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | (Amendment No. 1) |
Document Period End Date | Apr. 14, 2021 |
Entity File Number | 001-15771 |
Entity Registrant Name | ABEONA THERAPEUTICS INC. |
Entity Central Index Key | 0000318306 |
Entity Tax Identification Number | 83-0221517 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 1330 Avenue of the Americas |
Entity Address, Address Line Two | 33rd Floor |
Entity Address, City or Town | New York |
Entity Address, State or Province | NY |
Entity Address, Postal Zip Code | 10019 |
City Area Code | (646) |
Local Phone Number | 813-4701 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 par value |
Trading Symbol | ABEO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
9-B3,?V=$&:KX$D+ZP!@(
M^RTF;(]")-Y/B@C-'!\(\$-K(/$_4&\\/!J1D ^GE'.7U!$!ZN5E]D#L?V)B
M]^M\!>!O7MSUW5Y:X.RWB@#QOWLM^ _4(D7@@2HF$WM)5P#V!\9 ZF>8U#T*
M47G?B 1*>V,*SG_P8>_)0T+=9SHFO/"H;X_I,.X2 ^15T#:/@*!E^ZU>]][>"#AT6M@Z/?U#N;$O=?OE;/T@+CJV6O@E"0M5SZL
M]!Q)"X$WF3E"KAA9Y##6 CW<0UK*$:A!N]#ED@Q0C76QO>4]V (".&TIC3=I
M/QAG4M>Q\&@/V%C)+L^8753/A!41=I:F^[\W5<
M;L^!NA^/?2-OR!Y*'"77JQ:*2WZ@=4;5L?Q+2D&C@)+V0477/<[0.+/#WK+3
M'3VY'3.>4>; "LH:)>7SB:J9[9U\4L3MWALNTY'D_NTAI890PB@)7D!:S9!W
M_"C'NV<"!8N2V97*01H3;A;QE(@)]:]>*+>$ D;)]$+BT,;>"6CLG1PY]J)D
M?#Y12&R+M>'VC+H?<38A_IUDP0+@?3:8Q -2Z]Z_EV_Y<3N[59K[T;;S_G7+^
M6
5Q%TI2[+Z-K.!\R^ F+F>#SJ+<.SF7L"
M.@B#7-KL]4\M/,AF_V_0_93[X1''D?^_:(>&V?V
M'0?%EGK&(J!GM